NASDAQ · Biotechnology · USD

Benitec Biopharma Inc. (BNTC) Stock Analysis

Benitec Biopharma Inc. (BNTC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BNTC

$8.50

−$0.54 (−5.97%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BNTC with… →

BNTC Key Statistics

As of Oct 21, 2026

Trading

Open: $9.05
Previous Close: $9.04
Day's Range: 8.42–9.22
52-Week Range: 8.25–16.76
Volume: 171.85K
Beta: 0.25

Valuation

Market Cap: $295.11M
P/E Ratio: unprofitable
EPS (ttm): −0.94

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$37.92M
Shares Outstanding: 34.88M
1-Year Return: −46.41%

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 159.48K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BNTC closed at $8.50, −46.41% over 1 year.

Benitec Biopharma Inc. (BNTC) has a market capitalization of $295.11M.

In fiscal 2025, BNTC reported revenue of $0.00.

BNTC Stock Return by Calendar Year

Benitec Biopharma Inc. (BNTC) 10-year return: what $10,000 became

1 year: $10,000 $5,359; −46.41%
5 years: $10,000 $1,344; −86.56%
10 years: $10,000 $237; −97.63%

If you had invested $10,000 in Benitec Biopharma Inc. (BNTC) 10 years ago, at the close on October 21, 2016, it would have been worth $237 at the close on October 21, 2026: −97.63% in total, −31.23% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−93.51%+291.02%−36.90%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−36.90%
2025	+6.65%
2024	+291.02%
2023	+11.76%
2022	−93.51%
2021	−12.67%
2020	−60.78%
2019	−66.00%
2018	−49.27%
2017	+93.46%
2016 (partial year)	−11.51%

As of October 21, 2026.

BNTC Revenue and Earnings by Fiscal Year

FY ends June

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$37.92M	—
2024	$0.00	−$21.75M	—
2023	$75.00K	−$19.56M	−26,082.7%
2022	$73.00K	−$18.21M	−24,942.5%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$41.77M	−$37.92M	—
2024	$0.00	—	−$22.49M	−$21.75M	—
2023	$75.00K	$75.00K	−$19.08M	−$19.56M	−26,082.7%
2022	$73.00K	$64.00K	−$17.85M	−$18.21M	−24,942.5%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Benitec Biopharma Inc. (BNTC) carries a market capitalisation of $295.11M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 24.

The 52-week range on file runs from $8.25 to $16.76. The most recent close on file for BNTC is $8.50, dated October 21, 2026. That is −$0.54 (−5.97%) against the previous close. The latest close sits 3.03% above that 52-week low.

Financial Health

In fiscal 2025, Benitec Biopharma Inc. reported revenue of $0.00. The same year closed with a net loss of $37.92M. Trailing earnings per share are −0.94.

Across the 4 fiscal years on file, revenue moves from $73.00K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 0.25. Annualized volatility over the trailing 10 years is 131.7%. The trailing one-year total return is −46.41%. Across 10 years the annualized return works out at −31.23%.

Growth & Income

The dividend record for BNTC runs through 2018.

2026 is still running; the total return is −36.90% year to date. Across the complete calendar years on file, 2024 returned +291.02% and 2022 returned −93.51%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Benitec Biopharma Inc. (BNTC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Benitec Biopharma Inc.	BNTC	$295.11M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Benitec Biopharma Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Benitec Biopharma Inc.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Visit website →